Screener
Alnylam Pharmaceuticals ALNY Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 8:11 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001178670-26-000062
| (In thousands) | As of June 30, 2026 | As of June 30, 2025 |
|---|---|---|
| Cash and cash equivalents | $1,708,318 | $1,113,685 |
| Total restricted cash included in other assets | 1,160 | 2,176 |
| Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows | $1,709,478 | $1,115,861 |
Cover / Front Matter
FAQ
- What is Alnylam Pharmaceuticals's restricted cash?
- Alnylam Pharmaceuticals (ALNY) reported restricted cash of $1.16M in Q2 2026.
- How has Alnylam Pharmaceuticals's restricted cash changed year-over-year?
- Alnylam Pharmaceuticals's restricted cash decreased by 46.7% year-over-year, from $2.18M to $1.16M.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Alnylam Pharmaceuticals's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude